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Abstract
Background: Intra-articular inflammation resulting in lameness is a common health problem in horses. Exogenous
intra-articular hyaluronic acid has been shown to provide an analgesic effect and reduce pain in equine and human
osteoarthritis. High molecular weight non-animal stabilized hyaluronic acid (NASHA) has gained popularity in the
treatment of human arthritic conditions due to its long-acting pain-relieving effects. The aim of this study was to
compare the response to treatment of lameness localized in the equine metacarpophalangeal joint injected with
non-animal stabilized hyaluronic acid (NASHA) and placebo (saline). Twenty-seven clinically lame horses with a
positive response to diagnostic intra-articular anaesthesia of the metacarpophalangeal joint and with no, or at most
mild, radiographic changes in this joint were included in the study. Horses in the treatment group (n = 14) received
3 mL of a NASHA product intra-articularly, and those in the placebo group (n = 13) received an equivalent volume
of sterile 0.9 % saline solution.
Results: The change in the lameness score did not significantly differ between NASHA and placebo groups (P = 0.94).
Scores in the flexion test improved more in the NASHA group compared with placebo (P = 0.01). The changes in
effusion and pain in flexion were similar (P = 0.94 and P = 0.27, respectively) when NASHA and placebo groups were
compared. A telephone interview follow-up of the owners three months post-treatment revealed that 14 of the 21
horses (67 %) were able to perform at their previous level of exercise.
Conclusions: In the present study, a single IA NASHA injection was not better than a single saline injection for
reducing lameness in horses with synovitis or mild osteoarthritis. However, the results of this study indicate that IA
NASHA may have some beneficial effects in modifying mild clinical signs but more research is needed to evaluate
whether the positive effect documented ie. reduced response in the flexion test is a true treatment effect.
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Background
Over 70 % of racehorses suffer from lameness during their
lifetime, and the cause of this is often intra-articular in-
flammation [1]. Acute or repetitive overload injuries of the
metacarpo- or metatarsophalangeal joint can lead to syno-
vitis or capsulitis of the joint [2]. Damage to the articular
cartilage, subchondral bone, synovium, joint capsule or
other soft tissues of the joint may lead to degeneration [3].
Inflammation of articular soft tissues can result in the syn-
thesis of defective cartilage matrix components, leading to
osteoarthritis [4]. This may remain clinically silent for a
long period and only become clinically and radiographic-
ally evident when the disease has progressed to an irre-
versible state [5, 6]. Therefore, early detection and
treatment of the disease, as well as prevention of further
damage, is considered important.
Hyaluronan (HA) is a glycosaminoglycan that has an im-
portant role in the formation of proteoglycan aggregates in
the cartilage. It is also a component of the synovial fluid.
Synovial membrane type B cells and chondrocytes synthe-
tize HA by disaccharide oligomerization [7]. Hyaluronan
molecules restrict large plasma proteins from entering the
synovial fluid, but facilitate the passage of small molecules
for the maintenance of nutrition [8]. In osteoarthritis, the
synthesis of HA is disrupted by increased levels of pro-
inflammatory cytokines, free radicals and proteinases,
resulting in HA with a significantly reduced molecular
weight, more molecular polydisaccharides and a reduction
in synovial fluid viscoelasticity [9].
Exogenous intra-articular (IA) HA has been shown to
provide an analgesic effect and reduce pain in equine
[10–15] and human osteoarthritis [16–24]. It is believed
that exogenous HA stimulates the synthesis of HA by
synoviocytes and promotes proteoglycan synthesis by
chondrocytes [25]. HA can also indirectly contribute to
the viscosity of the synovial fluid and lubricate unloaded
joints. Furthermore, since the pain-relieving effect of IA
HA within the injected joint often persists for consider-
ably longer than the half-life of HA, it is likely that it
provides not only symptom-modifying but also disease-
modifying effects. The half-life of unmodified HA solu-
tions can be less than 1 day [26, 27]. Recently, a high
molecular weight non-animal stabilized hyaluronic acid
(NASHA) product) has gained popularity in the treat-
ment of human arthritic conditions due to its long-
acting pain relieving effects [8, 17, 18, 20–24].
Currently, only one double-blinded placebo-controlled
clinical equine study on IA HA treatment has been pub-
lished [15]. That study reported a superior effect of HA
and polysulphated glycosaminoglycan compared with
placebo in reducing the lameness score. Overall, the effi-
cacy of intra-articular HA in relieving inflammation and
pain has only been examined in a few clinical and ex-
perimental equine studies [11–15, 28, 29]. In horses with
medically induced synovitis, White et al. [28] found HA
to relieve lameness compared with placebo. However, in
a surgically induced equine osteoarthritis model, no
changes in the lameness score were detected after HA
treatment compared with a control treatment [29].
Some osteoarthritis models in animals have shown
that high molecular weight HA preparations are superior
to less polymerized HA forms [30, 31]. In a clinical
equine trial comparing HA preparations differing in mo-
lecular weight, better clinical results were reported using
HA of a higher molecular weight [32], but more research
on the different preparations is needed. In this study, a
NASHA product for human use (Durolane, Bioventus)
was used. It has a long half-life (up to 32 days) [33] and
remains in the synovial structures for a considerably lon-
ger period than other HA products [17, 18, 34].
We compared an IA injection of this NASHA product
with an IA injection of placebo. The aim of the study
was to examine whether the change in lameness origin-
ating from a metacarpophalangeal joint, from before the
injection to after the injection, would differ between the
two treatment groups. The IA injections were given on
the day of the clinical baseline examination and after
two weeks the horses returned for a second clinical
examination. Our hypothesis was that the outcome mea-
sures would improve more in the horses treated with
NASHA compared with those treated with placebo.
Methods
Design
The study was carried out as a randomised double-blind
and placebo-controlled trial with a parallel group design
and equal allocation ratio. It was planned and it is reported
according the CONSORT statement (http://www.consort-
statement.org/checklists/view/32-consort/). The study was
approved by the Viikki Campus Research Ethics Committee
of the University of Helsinki (31 March 2010). All horse
owners signed a study consent sheet before the start of the
study and owner was allowed to stop the study of the horse
without giving any particular reason. Reasons for removing
the horse from the study could have been side-effects
caused by the NASHA or placebo products, additional
orthopaedic or other health problems occurring after the
first clinical examination and/or owners’ lack of compliance
or failure to follow the instructions given after the first clin-
ical examination.
Population
Horses with lameness due to synovitis of the metacarpo-
or metatarsophalangeal joint, with or without mild
osteoarthritis, were recruited to the study. Synovitis of
all durations was acceptable. Only adult, non-geriatric
(i.e. age between 4–17 years), Finnhorse, Standardbred
and Warmblood horses of all disciplines were eligible. In
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addition, large-sized ponies (withers 140–148 cm) were
accepted (for convenience, referred to as horses in the
text). Inclusion criteria were a positive response to diag-
nostic intra-articular anaesthesia of the affected meta-
carpo- or metatarsophalangeal joint and no radiographic
signs of remodelling of the affected joint. This excluded
horses with more severe chronic osteoarthritis. In
addition, horses with intra-articular osteochondral or
other fragments were excluded. Bilaterally lame horses
and horses that had received intra-articular medications
such as corticosteroids or HA within the previous three
months, or per oral NSAIDs within 15 days, were not eli-
gible. Furthermore, horses with concurrent pathologies,
such as clinically significant ligament, tendon or other soft
tissue injuries in the affected limb, were excluded.
Clinical exam and interventions
The study was advertised at stables, via the Internet page of
the Faculty of the Veterinary Medicine [35], in equine
clinics and in horse sport magazines. Horse owners con-
tacted the University to have their horses included in the
study and a telephone interview was conducted. An assist-
ant not otherwise tied to the study enrolled the participants.
Within a week after the horse owners had contacted the
University to have their horses included, potential cases
were presented to the Veterinary Teaching Hospital of the
University of Helsinki for the first baseline clinical examin-
ation. This first examination was performed on the same
day that each horse arrived at the hospital.
The horses were subjected to a complete lameness exam-
ination by the evaluating veterinarian (TMN). A standard-
ized scale of 0–5 [36] was used to grade lameness. Effusion
of the affected joint was recorded on a scale of 0–4 (0 = no
effusion, 1 =mild, 2 =moderate, 3 = severe effusion, 4 = se-
vere swelling of the joint region) [28, 37]. Other palpation
findings, such as thickening of the joint capsule, were also
recorded (yes/no thickening). A flexion test of the affected
and the contralateral limb was performed and the lameness
was recorded on a scale of 0–4 (0 = no increase, 1 = slight
increase, 2 =moderate increase, 3 = considerable increase in
the baseline lameness, 4 = non-weight-bearing lameness)
[29]. To exclude confounding flexing reactions, for instance
because of sensitiveness to handling, and thereby help the
researchers to evaluate the reaction of the affected limb, the
contralateral non-lame leg was always flexed first. The re-
sult of this contralateral flexion test was not recorded.
Pain when flexing the affected distal limb was also re-
corded on a scale of 0–3. This pain score was created by
the authors and was recorded as follows: 0 = no pain on
flexion, 1 =mild pain, i.e. the horse shows some reaction,
such as moving the limb, 2 =moderate pain, i.e. the
horse retracts the limb repeatedly during the 1 min
flexion period, 3 = severe pain, i.e. the flexion test cannot
be properly performed.
To localize the lesion and to decide if the horse was eli-
gible for the study, a routine diagnostic aseptic arthrocent-
esis with an 18-gauge/3.8-cm needle was performed
through the lateral sesamoidean ligament and 10 mL mepi-
vacaine hydrochloride (Scandicain, Astra Zeneca) was
injected into the joint. The response to the intra-articular
anaesthesia was evaluated 10 min post-injection and was
considered positive if a subjectively evaluated 80–100 %
amelioration of lameness was evident. Radiographic exam-
ination of the joint with four standard views was performed
(lateromedial, dorsopalmar, dorsolateral-palmaromedial
and dorsomedial-palmarolateral), and all radiographs were
evaluated by the same veterinarian (TMN).
Before starting the study, a non-blinded assisting tech-
nician created a computer generated randomization list
using an Internet-based program [38]. The block size
was 4 and no strata were used. Horses fulfilling the in-
clusion criteria were assigned to the treatment or control
group according to the randomization list. The list and
the NASHA and placebo products were kept in a locked
locker at the university that only the non-blinded assist-
ing veterinarian and his technician could access. Horses in
the treatment group were injected with 3 mL NASHA
into the affected joint, while horses in the control group
received an equivalent volume of the sterile 0.9 % saline
solution (Sodium chloride 9 mg/mL, B Braun) into the
joint. Injections were administered on the same day that
each horse arrived at the hospital, after confirming eligibil-
ity, the source of lameness and evaluating the radiographs.
Treatments were double-blinded so that the assisting
veterinarian prepared the syringes according to the
randomization list and performed the NASHA and sa-
line injections, and neither the evaluating veterinarian
(TMN) nor the owners were allowed in the treatment
room during the procedure. Owners remained blinded
until after the second clinical examination and the evalu-
ating veterinarian (TMN) until after the statistical ana-
lyses were performed.
Second clinical examination and follow-up
Horses were allowed 30 min hand-walking per day and
free access to a small paddock during the following two
weeks, after which the second clinical examination was
performed. Palpation findings and other outcome mea-
sures were re-evaluated and recorded (TMN). After the
second clinical examination, the double-blinded trial
part was concluded and the horses in the control group
also received an IA NASHA injection to treat the lame-
ness. To ensure that all treatment injections were per-
formed by the same veterinarian, the assisting
veterinarian also injected the placebo group with the
NASHA. Follow-up information was collected two and a
half to three months post-treatment by interviewing all
owners by telephone.
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The primary outcome measure was the change in the
lameness score from baseline to the second clinical
examination in the two intervention groups. The sec-
ondary outcome measures were the change in the effu-
sion of the affected joint, in the lameness after the
flexion test and in pain in flexion from baseline to the
second clinical examination.
Statistical methods
A sample size calculator [39] was used with a 95 % confi-
dence level and 80 % power, and the sample size was esti-
mated at 11–14 horses per group based on 87 % of cases
showing clinical improvement in an earlier study on HA
for the treatment of naturally occurring arthritic condi-
tions in horses [13]. In the placebo group, the proportion
that would improve was estimated to be 20–30 %, where
20 % is 10 % lower than the percentage that has been used
in the placebo groups in human studies [40, 41].
Data analysis was performed with a computer-based
statistical program (SPSS Software, IBM). The final
values for the outcome measures were subtracted from
the baseline values to form variables of change, allowing
positive and negative values. These variables of change
were used in the comparison between groups with the
independent-samples Mann–Whitney U-test (ranks).
The demographic data and outcome measures at base-
line were compared between the two treatment groups
using the independent-samples Mann–Whitney U-test,
or in the case of nominal categorical variables, Fisher’s
exact test or the likelihood ratio test. Furthermore, the
outcome measures within groups were compared be-
tween the baseline examination and the second clinical
examination using the Wilcoxon signed-rank test. All
the above statistics were calculated for the population
intended to treat (n = 30) and for the metacarpophalan-
geal patients only (n = 27). Value of P < 0.05 was consid-
ered significant.
Results
Sixty-eight horse owners were interviewed, which re-
sulted in 36 horses being invited to the first clinical
baseline examination. Altogether, 30 horses fulfilling the
inclusion criteria were included in the study. However,
as only three horses that concluded the study had lame-
ness due to synovitis of the metatarsophalangeal joint,
these were omitted from some of the analyses, leaving
27 horses with synovitis of the metacarpophalangeal
joint as the primary study population (Table 1, Fig. 1).
All the 27 horses completed the study. For the included
horses, all examinations were performed between May
2010 and May 2012.
In 16 horses, lameness had previously been localised
to the joint from which the lameness originated at base-
line. Fifteen horses had received HA and/or corticoster-
oid treatment more than 3 months before entering the
study in the same joint from which the lameness origi-
nated at baseline, while nine horses had not previously
received any medications for musculoskeletal problems.
No significant differences in signalment, the use of the
horse, outcome measures or the number of horses with
findings in radiographs were found between the NASHA
and placebo treatment groups at the first clinical (base-
line) examination (Table 1). The baseline lameness score
ranged from 1 to 3 (out of 0–5) and the most frequent
lameness score was 2 (n = 13, 48 %). In 7 (26 %) horses,
the lameness score was 1 and in 7 (26 %) cases 3.
When the change in the lameness score as the primary
outcome measure was compared between the NASHA
Table 1 Demographic variables and outcome measures in the first clinical baseline examination of the placebo and NASHA groups
(n = 27) and P-values for the comparison between treatment groups at the first clinical baseline examination
Variable Placebo NASHA P-value
Number of horses 13 14
Age (~years): Mean (range) 8.4 (4–17) 7.2 (4–12) 0.55
Gender: Mare/Stallion/Gelding % 46 %/15 %/39 % 43 %/21 %/36 % 0.09
Purpose: Harness race horse/Riding horse % 54 %/46 % 71 %/29 % 0.44
Breed: Standardbred/Finnhorse/Wamblood/Pony % 31 %/39 %/15 %/15 % 43 %/50 %/7 %/0 % 0.65
Affected limb: RF/LF % 46 %/54 % 71 %/29 % 0.25
Baseline lameness (AAEP)a: 0/1/2/3/4/5 % 0 %/15 %/39 %/46 %/0 %/0 % 0 %/36 %/57 %/7 %/0 %/0 % 0.05
Effusionb: 0/1/2/3/4 % 23 %/46 %/0 %/31 %/0 % 29 %/29 %/35 %/7 %/0 % 0.83
Lameness in the flexion testc: 0/1/2/3/4 % 0 %/0 %/8 %/61 %/31 % 0 %/0 %/29 %/50 %/21 % 0.33
Pain in flexiond: 0/1/2/3 % 0 %/31 %/23 %/46 % 7 %/29 %/36 %/28 % 0.46
Mild findings in radiographs: Yes/No % 54 %/46 % 50 %/50 % 1.00
a AAEP scale 0–5
b 0 = no effusion, 1 =mild, 2 = moderate, 3 = severe effusion, 4 = severe swelling of the metacarpal joint region
c 0 = no increase, 1 = slight increase, 2 =moderate increase, 3 = considerable increase in baseline lameness, 4 = non-weight-bearing lameness
d 0 = no pain at flexion, 1 =mild pain, 2 =moderate pain, 3 = severe pain
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and the placebo groups, no significant difference was
seen (P = 0.94, Table 2). When the changes in the sec-
ondary outcome measures were compared respectively, a
significant difference was recorded for the change in the
response to the flexion test (P = 0.01, Table 2). In con-
trast, the change in effusion and in the pain in flexion
was similar in the placebo and NASHA groups (P = 0.94
and P = 0.27, respectively, Table 2). All results were simi-
lar when the three horses with metatarsophalangeal joint
problems had been included.
No adverse effects of either intra-articular NASHA or
saline injection could be seen in any of the horses. Based
on the follow-up telephone interview at 2.5–3 months,
14 of the 21 horses (67 %) had been able to return to
their previous level of use, but two of these had later de-
veloped other musculoskeletal problems. Six horse
owners were not reached for the follow-up interview.
Seven of the 21 horses (33 %) were no longer used in
the same discipline or at the same performance level.
Discussion
In this study, the effect of intra-articular NASHA in re-
lieving synovitis and lameness in clinical patients was
evaluated. Apart from the study of Gaustad and Larsen
[15], this is to our knowledge the only double-blinded
placebo-controlled clinical equine study on intra-
articular HA, and this study focused on a single joint.
Although the difference in the baseline lameness score
Fig. 1 Flow diagram showing the number of horses in different phases of the study. MCPJ =metacarpophalangeal joint; MTPJ =metatarsophalangeal
joint
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was almost statistically significant, the groups of the present
study were comparable (Table 1), as the baseline clinical
and demographic variables did not significantly differ be-
tween them. This is important in a clinical study, since
variables such as the level of physical activity of the horses
cannot be fully controlled for. Gaustad and Larsen [15] also
reported comparable treatment groups in their study (n =
77), but the HA treatment group (n = 28) was not separated
from the PSGAG group (n = 27). Moreover, their study in-
cluded horses with traumatic arthritis as well as other diag-
noses in several high motion joints but the distribution of
diagnoses between groups was not reported.
Most of the previous studies on IA HA treatment in
horses are not comparable with the present study, since
only two of them [15, 28] were blinded placebo-
controlled studies and only one of the clinical studies
[14] focused on a single joint. Furthermore, White et al.
[28] used a prospective experimental study design with
only 4 horses per group. Lameness was evaluated by
measuring stride length, and not using the more subject-
ive but, standardised, AAEP scale [36], which also takes
into account the weight-bearing component of lameness.
As in the present study, Gaustad and Larsen [15] found
a significantly reduced lameness score in both the treat-
ment and placebo groups. However, in contrast to their
study, improvement in the lameness score of horses
injected IA with NASHA in the present study, was not
better than in the placebo group. The different result in
the study of Gaustad and Larsen [15] might be explained
by the more severe mean baseline lameness, the larger
sample size, the multiple joints involved, or the presence
of different joint diseases, compared with the present
study. As in our study, Frisbie et al. [29] reported a lack
of improvement in the lameness score with respect to
treatment when HA was administered to horses with ex-
perimentally induced osteoarthritis. However, histologi-
cally, significantly less cartilage fibrillation was seen with
HA treatment compared with controls [29].
A response to the flexion test was the only outcome
measure which improved more in the NASHA group
compared with the placebo group (Table 2). In addition
to the lameness score, the flexion pain score improved
both within the placebo and the NASHA groups
(Table 2). It is possible that saline by itself might have
had a positive effect, as also shown by Gaustad et al.
[42]. They reported a significant improvement in horses
with arthritis after repeated injections of a 2 mL NaCl
solution. There was also a significant decrease in the
lameness score when this NaCl-injected group was com-
pared with the rest-only group. The synovial membrane
has been shown to respond to IA injections of saline,
and an increase in the synovial fluid HA concentration
after an injection of saline into equine joints has been
reported [43]. Furthermore, in both the study of Gaustad
et al. [42] and the present study, the therapeutic effect of
the local anaesthetic cannot be excluded. However, the
improvement also seen in the placebo group might be ex-
plained by the two weeks of light exercise (half an hour of
hand-walking per day) between clinical examinations,
which may have been sufficient to improve relatively low-
grade lameness, especially in harness racehorses undergo-
ing heavy training. Furthermore, our study design was
based on the assumption of a large difference in lameness
improvement between groups based on an earlier study of
HA for the treatment of naturally occurring arthritic con-
dition in horses [13], so our originally calculated number
of cases was probably too low to show smaller differences
between groups.
Despite the lack of improvement in the other outcome
measures of the present study, the greater improvement
in the flexion test score in the NASHA group (Table 2)
shows that IA NASHA may have some beneficial clinical
sign modifying effects. Flexion tests are an integral part
of a lameness examination. Although flexion tests may
have some limitations, the distal limb flexion test has
been shown to be very specific for the disease and the
pain arising from the metacarpophalangeal joint [44].
Treatment with high molecular weight IA HA is of
interest in human orthopaedics, and recent research has
demonstrated it to be effective and long-acting in the
Table 2 Medians (and ranges) of outcome measures in the placebo and NASHA groups, with P-values for the within-groups
comparison of outcome measures between the first baseline and second clinical (end) examination, and P-values for the comparison
between groups (P of change between interventions) of the change in outcome measures after the second clinical examination
Outcome
measure
Placebo
baseline
Placebo
end
P within
placebo
NASHA
baseline
NASHA
end
P within
NASHA
P for change between
interventions
Lamenessa 2 (1–3) 2 (0–3) 0.005 2 (1–3) 0 (0–3) 0.02 0.94
Effusionb 1 (0–3) 1 (0–3) 0.48 1 (0–3) 1 (0–3) 0.56 0.94
Flexion testc 3 (2–4) 3 (1–4) 0.07 3 (2–4) 1 (0–3) 0.002 0.01
Paind 2 (1–3) 1 (0–3) 0.04 2 (0–3) 0 (0–2) 0.01 0.27
a AAEP scale 0–5
b 0 = no effusion, 1 =mild, 2 = moderate, 3 = severe effusion, 4 = severe swelling of the metacarpal joint region
c 0 = no increase,1 = slight increase, 2 =moderate increase, 3 = considerable increase in baseline lameness, 4 = non-weight-bearing lameness
d 0 = no pain at flexion, 1 =mild pain, 2 =moderate pain, 3 = severe pain
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treatment of human osteoarthritis [20–24]. Based on
cross-linking, the NASHA has a prolonged residence
time and results in a viscous HA gel in the joint [34].
Previously, exogenous HA has been shown to disappear
from the joint within seven days [45], and synovitis also
enhances the clearance of HA from the joint [46]. How-
ever, Altman et al. [18] found a prolonged reduction in
pain after a NASHA treatment in human knee osteo-
arthritis patients with a maximum effect at 6 weeks
post-treatment. Similarly, Gaustad and Larsen [15] re-
ported that a significant number of horses became
sound between 3 and 6 weeks post-injection. Exogenous
HA has also been shown to increase the synthesis of HA
by human synovial cell lines, which could explain the
prolonged effect of exogenous HA [47]. Thus, the im-
provement in lameness in the NASHA group might have
been greater if the period between the examinations in
the present study had been longer than 2 weeks. How-
ever, since our study population consisted of clinical
client-owned patients, it would have been unethical to
delay the treatments of the horses receiving placebo for
a longer period and all the first placebo-injected horses
were therefore treated at the second examination. The
third assessment was performed as a telephone interview
to avoid long-distance travel for many of the patients.
Most horses (14 of 21, i.e. 67 %) were able to perform at
their previous level based on subjective assessment by
owners or trainers.
A clinical study design sets limits on a placebo-control
set-up. In addition, the lack of significant difference in
the change of lameness score between the NASHA and
placebo groups also reflects the difficulty in conducting
clinical studies, as variation between intervention groups
is always inevitably present, despite the lack of a statisti-
cally significant difference in demographic variables and
in baseline outcome measures, as in the present study
(Table 1). The severity of the disease can vary, despite a
uniform lameness score or other clinical scores.
Selection bias was minimized by recruiting horses
through several media and from a variety of riding and
racehorse stables around southern Finland. On the other
hand, this may also have caused a selection of horses
which have been unresponsive to previous treatments or
a selection of horse owners or trainers who overall train
their horses differently compared with the general horse
owner or trainer population. The population in the
present study may also have been too heterogeneous, i.e.
with variety of disciplines, training levels and training
conditions may have caused excessive variation in the
response to the NASHA injection and in the lack of a
significant difference in most of the outcome measures.
No adverse effects of the intra-articular NASHA injec-
tion could be seen in any of the horses. A transient
treatment related adverse effect of IA HA has been
reported in up to 10.0 % of cases in an equine study [13]
and 12.5 % in a human NASHA study [18].
Conclusions
In the present study, a single IA NASHA injection was
not better than IA saline for reducing lameness in horses
with synovitis or mild osteoarthritis in the metacarpopha-
langeal joint. However, this study shows indication that it
may have some beneficial effects in modifying clinical
signs. A single IA injection of NASHA might be useful in
the treatment of acute synovitis, but more research is
needed on the effects of NASHA in other equine joint dis-
ease states as well as on its mechanism of action.
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